Chemours Co Financials
This page shows Chemours Co (CC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Chemours Co's revenue declined 4.9% year-over-year, from $6.1B to $5.8B. This contraction results in a growth score of 15/100.
Chemours Co has elevated debt relative to equity (D/E of 6.91), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Chemours Co's current ratio of 1.66 indicates adequate short-term liquidity, earning a score of 46/100. The company can meet its near-term obligations, though with limited headroom.
While Chemours Co generated -$633.0M in operating cash flow, capex of $360.0M consumed most of it, leaving -$993.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Chemours Co's ROE of 11.9% shows moderate profitability relative to equity, earning a score of 48/100.
Chemours Co passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Chemours Co generates $-9.04 in operating cash flow (-$633.0M OCF vs $70.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Chemours Co generated $5.8B in revenue in fiscal year 2024. This represents a decrease of 4.9% from the prior year.
Chemours Co generated -$993.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 633.9% from the prior year.
Chemours Co reported $70.0M in net income in fiscal year 2024. This represents an increase of 129.4% from the prior year.
Chemours Co earned $0.47 per diluted share (EPS) in fiscal year 2024. This represents an increase of 129.4% from the prior year.
Chemours Co held $713.0M in cash against $4.1B in long-term debt as of fiscal year 2024.
Chemours Co paid $1.00 per share in dividends in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Chemours Co had 149M shares outstanding in fiscal year 2024. This represents an increase of 0.6% from the prior year.
Chemours Co's gross margin was 19.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 1.7 percentage points from the prior year.
Chemours Co's net profit margin was 1.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 5.1 percentage points from the prior year.
Chemours Co's ROE was 11.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Chemours Co invested $109.0M in research and development in fiscal year 2024. This represents an increase of 0.9% from the prior year.
Chemours Co invested $360.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 2.7% from the prior year.
CC Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B-7.4% | $1.6B+18.1% | $1.4B+0.7% | $1.4B-0.7% | $1.4B-8.9% | $1.5B-9.6% | $1.7B+7.2% | $1.5B |
| Cost of Revenue | $1.3B-5.6% | $1.3B+18.1% | $1.1B+4.2% | $1.1B-2.4% | $1.1B-9.4% | $1.2B-1.8% | $1.3B+5.8% | $1.2B |
| Gross Profit | $233.0M-16.2% | $278.0M+17.8% | $236.0M-13.6% | $273.0M+7.1% | $255.0M-6.6% | $273.0M-33.4% | $410.0M+11.4% | $368.0M |
| R&D Expenses | $26.0M-7.1% | $28.0M+3.7% | $27.0M+3.8% | $26.0M0.0% | $26.0M-7.1% | $28.0M0.0% | $28.0M+7.7% | $26.0M |
| SG&A Expenses | $109.0M-75.1% | $437.0M+255.3% | $123.0M-27.6% | $170.0M-22.0% | $218.0M+32.1% | $165.0M-78.8% | $779.0M+528.2% | $124.0M |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $68.0M+1.5% | $67.0M+1.5% | $66.0M0.0% | $66.0M+4.8% | $63.0M+14.5% | $55.0M+14.6% | $48.0M+14.3% | $42.0M |
| Income Tax | -$9.0M-107.6% | $119.0M+2875.0% | $4.0M-63.6% | $11.0M+120.8% | -$53.0M-5400.0% | $1.0M+101.8% | -$57.0M-303.6% | $28.0M |
| Net Income | $60.0M+115.7% | -$381.0M-9425.0% | -$4.0M+50.0% | -$8.0M+55.6% | -$18.0M-250.0% | $12.0M+103.2% | -$376.0M-359.3% | $145.0M |
| EPS (Diluted) | $0.40+115.7% | $-2.54-8366.7% | $-0.03+40.0% | $-0.05+58.3% | $-0.12-250.0% | $0.08+103.2% | $-2.52-362.5% | $0.96 |
CC Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6B+1.1% | $7.5B+1.3% | $7.4B-1.6% | $7.5B-9.0% | $8.3B+3.8% | $7.9B+3.8% | $7.7B+0.5% | $7.6B |
| Current Assets | $3.2B+3.5% | $3.1B+5.7% | $2.9B-2.8% | $3.0B-21.5% | $3.8B+4.4% | $3.7B+9.2% | $3.4B+5.4% | $3.2B |
| Cash & Equivalents | $613.0M+22.1% | $502.0M+8.2% | $464.0M-34.9% | $713.0M-40.7% | $1.2B+41.2% | $852.0M+15.4% | $738.0M-9.6% | $816.0M |
| Inventory | $1.5B-0.7% | $1.6B+0.5% | $1.6B+5.9% | $1.5B+8.5% | $1.3B+2.7% | $1.3B-9.1% | $1.4B-2.7% | $1.5B |
| Accounts Receivable | $817.0M+0.5% | $813.0M+15.5% | $704.0M+13.7% | $619.0M+21.6% | $509.0M-32.4% | $753.0M-3.7% | $782.0M+8.3% | $722.0M |
| Goodwill | $46.0M0.0% | $46.0M0.0% | $46.0M0.0% | $46.0M-54.9% | $102.0M0.0% | $102.0M0.0% | $102.0M0.0% | $102.0M |
| Total Liabilities | $7.3B+0.3% | $7.2B+6.4% | $6.8B-1.6% | $6.9B-7.9% | $7.5B+4.4% | $7.2B+5.1% | $6.8B+7.1% | $6.4B |
| Current Liabilities | $1.9B+1.6% | $1.9B+10.6% | $1.7B-7.9% | $1.8B-26.9% | $2.5B-15.0% | $2.9B+33.6% | $2.2B+25.5% | $1.7B |
| Long-Term Debt | $4.1B-0.1% | $4.1B+0.9% | $4.1B+0.2% | $4.1B+1.6% | $4.0B+1.1% | $3.9B+9.4% | $3.6B+0.1% | $3.6B |
| Total Equity | $298.0M+25.7% | $237.0M-59.1% | $579.0M-1.4% | $587.0M-20.2% | $736.0M-2.5% | $755.0M-6.6% | $808.0M-34.1% | $1.2B |
| Retained Earnings | $1.3B+3.7% | $1.3B-23.7% | $1.7B-2.5% | $1.7B-4.5% | $1.8B-3.0% | $1.8B-1.4% | $1.9B-18.2% | $2.3B |
CC Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $146.0M+57.0% | $93.0M+183.0% | -$112.0M-181.2% | $138.0M-71.4% | $482.0M+267.9% | $131.0M+95.5% | $67.0M+154.0% | -$124.0M |
| Capital Expenditures | $41.0M-4.7% | $43.0M-48.8% | $84.0M-22.9% | $109.0M-19.3% | $135.0M+57.0% | $86.0M+48.3% | $58.0M-36.3% | $91.0M |
| Free Cash Flow | $105.0M+110.0% | $50.0M+125.5% | -$196.0M-775.9% | $29.0M-91.6% | $347.0M+671.1% | $45.0M+400.0% | $9.0M+104.2% | -$215.0M |
| Investing Cash Flow | -$35.0M+16.7% | -$42.0M+51.2% | -$86.0M+19.6% | -$107.0M+17.7% | -$130.0M-324.1% | $58.0M+196.7% | -$60.0M+38.1% | -$97.0M |
| Financing Cash Flow | -$5.0M+81.5% | -$27.0M+52.6% | -$57.0M-167.1% | $85.0M+1800.0% | -$5.0M-101.5% | $324.0M+510.1% | -$79.0M-16.2% | -$68.0M |
| Dividends Paid | $13.0M0.0% | $13.0M-64.9% | $37.0M+2.8% | $36.0M-2.7% | $37.0M0.0% | $37.0M-2.6% | $38.0M+2.7% | $37.0M |
| Share Buybacks | N/A | N/A | N/A | N/A | $0-100.0% | $18.0M-51.4% | $37.0M+164.3% | $14.0M |
CC Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 15.6%-1.6pp | 17.2%-0.0pp | 17.3%-2.8pp | 20.1%+1.4pp | 18.6%+0.5pp | 18.2%-6.5pp | 24.7%+0.9pp | 23.8% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 4.0%+27.6pp | -23.6%-23.3pp | -0.3%+0.3pp | -0.6%+0.7pp | -1.3%-2.1pp | 0.8%+23.5pp | -22.7%-32.0pp | 9.4% |
| Return on Equity | 20.1%+11.7pp | 8.4%+1.2pp | 7.2% | N/A | N/A | 1.6% | N/A | 11.8% |
| Return on Assets | 0.8%+5.9pp | -5.1%-5.0pp | -0.1%+0.1pp | -0.1%+0.1pp | -0.2%-0.4pp | 0.1%+5.1pp | -4.9%-6.8pp | 1.9% |
| Current Ratio | 1.71+0.0 | 1.68-0.1 | 1.75+0.1 | 1.66+0.1 | 1.55+0.3 | 1.26-0.3 | 1.54-0.3 | 1.83 |
| Debt-to-Equity | 13.75-3.6 | 17.31+10.3 | 7.02+0.1 | 6.91+1.5 | 5.42+0.2 | 5.22+0.8 | 4.46+1.5 | 2.93 |
| FCF Margin | 7.0%+3.9pp | 3.1%+17.4pp | -14.3%-16.5pp | 2.1%-23.2pp | 25.4%+22.4pp | 3.0%+2.5pp | 0.5%+14.4pp | -13.9% |
Similar Companies
Frequently Asked Questions
What is Chemours Co's annual revenue?
Chemours Co (CC) reported $5.8B in total revenue for fiscal year 2024. This represents a -4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Chemours Co's revenue growing?
Chemours Co (CC) revenue declined by 4.9% year-over-year, from $6.1B to $5.8B in fiscal year 2024.
Is Chemours Co profitable?
Yes, Chemours Co (CC) reported a net income of $70.0M in fiscal year 2024, with a net profit margin of 1.2%.
What is Chemours Co's earnings per share (EPS)?
Chemours Co (CC) reported diluted earnings per share of $0.47 for fiscal year 2024. This represents a 129.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
How much debt does Chemours Co have?
As of fiscal year 2024, Chemours Co (CC) had $713.0M in cash and equivalents against $4.1B in long-term debt.
What is Chemours Co's gross margin?
Chemours Co (CC) had a gross margin of 19.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Chemours Co's net profit margin?
Chemours Co (CC) had a net profit margin of 1.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
Does Chemours Co pay dividends?
Yes, Chemours Co (CC) paid $1.00 per share in dividends during fiscal year 2024.
What is Chemours Co's return on equity (ROE)?
Chemours Co (CC) has a return on equity of 11.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Chemours Co's free cash flow?
Chemours Co (CC) generated -$993.0M in free cash flow during fiscal year 2024. This represents a -633.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Chemours Co's operating cash flow?
Chemours Co (CC) generated -$633.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Chemours Co's total assets?
Chemours Co (CC) had $7.5B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Chemours Co's capital expenditures?
Chemours Co (CC) invested $360.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Chemours Co spend on research and development?
Chemours Co (CC) invested $109.0M in research and development during fiscal year 2024.
How many shares does Chemours Co have outstanding?
Chemours Co (CC) had 149M shares outstanding as of fiscal year 2024.
What is Chemours Co's current ratio?
Chemours Co (CC) had a current ratio of 1.66 as of fiscal year 2024, which is generally considered healthy.
What is Chemours Co's debt-to-equity ratio?
Chemours Co (CC) had a debt-to-equity ratio of 6.91 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Chemours Co's return on assets (ROA)?
Chemours Co (CC) had a return on assets of 0.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Chemours Co's cash runway?
Based on fiscal year 2024 data, Chemours Co (CC) had $713.0M in cash against an annual operating cash burn of $633.0M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Chemours Co's Piotroski F-Score?
Chemours Co (CC) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Chemours Co's earnings high quality?
Chemours Co (CC) has an earnings quality ratio of -9.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Chemours Co?
Chemours Co (CC) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.